Literature DB >> 32767257

Tumor cell-expressed IL-15Rα drives antagonistic effects on the progression and immune control of gastric cancer and is epigenetically regulated in EBV-positive gastric cancer.

Jing Wei1, Chen Guo1, Xiang An1, Wenxuan Miao2, Chenli Zhang1, Binsheng Wang3, Wei Cai4, Min Li5,6, Fangfang Zhang7,8.   

Abstract

PURPOSE: Epstein-Barr virus associated gastric cancer (EBVaGC) often exhibits a favorable prognosis that correlates with highly methylated viral and host genes and significant immune cell infiltration compared to EBV-negative gastric cancers (GCs). Previously, it has been reported that expression of the IL-15 receptor α (IL-15Rα) is down-regulated in EBVaGC via promoter hypermethylation. In the present study, we offer a novel explanation for this puzzle by associating IL-15Rα expression with infiltration of lymphocytes in GC lesions.
METHODS: We investigated the expression of IL-15Rα by RT-PCR, Western-blotting and immunohistochemistry in GC cell lines and primary tissues, respectively. IL-15Rα promoter methylation was analyzed using genomic methylation sequencing. The growth behavior of GC cells was analyzed using MTT, flow cytometry, colony formation, transwell invasion and scratch wound healing assays. Demethylation of IL-15Rα was carried out using 5-Aza-CdR, and rIL-15 was added to evaluate growth promoting effects of the IL-15/IL-15Rα complex. Human peripheral blood mononuclear cells (PBMCs) were co-cultured with GC cells with/without the addition of rIL-15, after which the phosphorylation of STAT5 in PBMCs was evaluated using flow cytometry to estimate the activation of these immune cells through IL-15 binding to IL-2Rβ/γ receptors by in trans presentation.
RESULTS: We found that EBV-positive GC cells (AE) expressed IL-15Rα at a significantly lower level than EBV-negative GC cells (AGS) due to promoter hypermethylation. In the absence of immune cells, IL-15Rα on the cancer cell surface induced a malignant phenotype, including augmented cell growth, migration and invasion, and decreased apoptosis. 5-Aza-CdR reverted AE cells to a more malignant phenotype similar to AGS cells, which may be attributed to activation of the STAT1, STAT3 and ERK1/2 pathways. However, when PBMCs were added to the GC cell cultures, these immune cells were activated as detected by increased pSTAT5 levels. Also, more GC cells underwent apoptosis. These effects were enhanced by the addition of rIL-15 and, subsequently, confirmed in EBVaGC patient samples exhibiting increased expression of T cell surface markers and activation of immune co-stimulating pathways.
CONCLUSIONS: Our findings suggest a mechanistic explanation for the clinical association of EBVaGC with a lower IL-15Rα expression, a better prognosis and an increased lymphocyte infiltration. We propose that in highly infiltrated GCs the IL-15/IL-15Rα complex on the GC cell surface may present IL-15 in trans to IL-2Rβ/γ-expressing immune cells to activate these cells in the tumor microenvironment.

Entities:  

Keywords:  EBVaGC; Gastric cancer; IL15-Rα; Methylation; PBMCs; Presentation in trans

Mesh:

Substances:

Year:  2020        PMID: 32767257     DOI: 10.1007/s13402-020-00542-4

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  41 in total

1.  ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.

Authors:  Claire L Sutherland; Brian Rabinovich; N Jan Chalupny; Pierre Brawand; Robert Miller; David Cosman
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

Review 3.  IL-15/IL-15 receptor biology: a guided tour through an expanding universe.

Authors:  Vadim Budagian; Elena Bulanova; Ralf Paus; Silvia Bulfone-Paus
Journal:  Cytokine Growth Factor Rev       Date:  2006-06-30       Impact factor: 7.638

Review 4.  Cytokines and immunodeficiency diseases.

Authors:  W J Leonard
Journal:  Nat Rev Immunol       Date:  2001-12       Impact factor: 53.106

Review 5.  Interleukin-15 and the regulation of lymphoid homeostasis.

Authors:  James Lodolce; Patrick Burkett; Rima Koka; David Boone; Marcia Chien; Faye Chan; Michelle Madonia; Sophia Chai; Averil Ma
Journal:  Mol Immunol       Date:  2002-12       Impact factor: 4.407

Review 6.  The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy.

Authors:  Thomas A Waldmann
Journal:  Cancer Immunol Res       Date:  2015-03       Impact factor: 11.151

Review 7.  Interleukin-2, interleukin-15, and their roles in human natural killer cells.

Authors:  Brian Becknell; Michael A Caligiuri
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

Review 8.  Epstein-Barr virus-associated epithelial and mesenchymal neoplasms.

Authors:  Andrea T Deyrup
Journal:  Hum Pathol       Date:  2008-04       Impact factor: 3.466

9.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

10.  IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers.

Authors:  Pierfrancesco Marra; Sumi Mathew; Anita Grigoriadis; Yin Wu; Fernanda Kyle-Cezar; Johnathan Watkins; Mamunur Rashid; Emanuele De Rinaldis; Sonya Hessey; Patrycja Gazinska; Adrian Hayday; Andrew Tutt
Journal:  Cancer Res       Date:  2014-06-30       Impact factor: 12.701

View more
  1 in total

1.  A Novel Gene Signature of Tripartite Motif Family for Predicting the Prognosis in Kidney Renal Clear Cell Carcinoma and Its Association With Immune Cell Infiltration.

Authors:  Di Zheng; Yunlong Zhang; Yuqi Xia; Fan Cheng
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.